Competitive AdvantageCMP-CPS-001 has the ability to replace poorly performing, burdensome nitrogen scavenger therapy with a convenient monthly SC injection, and with a wider addressable population and favorable safety profile.
InnovationCAMP4 is pioneering development of regulatory RNAs (regRNAs) as a novel therapeutic modality.
Market OpportunityCMP-CPS-001 has a larger total addressable market and meets a high unmet need in urea cycle disorders, which presents an upside risk and reward opportunity.